Neumora Therapeutics, Inc. NMRA
Neumora Therapeutics, Inc. (Nasdaq: NMRA) is a CNS/neurology/psychiatry drug developer. Its lead program, NMRA-511, is in Phase 1 for Agitation in Alzheimer's disease (V1aR antagonist). Its next catalyst on record is NMRA-898: NMRA-898 Phase 1 MAD data expected in the second half of 2026. (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: NMRA-898 — NMRA-898 Phase 1 MAD data expected in the second half of 2026. (H2 2026). 4 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| navacaprant | MDD | small molecule | Phase 3 |
| NMRA-511 | AD agitation | small molecule | Phase 1 |
| NMRA-898 | Schizophrenia (M4 PAM) | small molecule | Phase 1 |
| NMRA-215 | Obesity (NLRP3) | small molecule | Phase 1 |
| NMRA-GCase | Neurodegeneration | small molecule | Pre-clinical |
| NMRA-CK1d | Neurodegeneration | small molecule | Pre-clinical |
Recent results and decisions
- Jun 15, 2026missed KOASTAL-2 missed primary MADRS endpoint at week 6: -12.2 vs -12.0 placebo, LSMD -0.3, p=0.813
In the KOASTAL-2 study patients treated with navacaprant 80 mg (n = 217) demonstrated a similar CFB to those treated with placebo (n = 213) [-12.2 vs -12.0; least-squares mean difference (LSMD) = -0.3; p = 0.813].
Filing - Jun 15, 2026discontinued Company discontinuing navacaprant development after KOASTAL-2 and -3 failures; 35% workforce reduction
The Company is discontinuing development of navacaprant as it continues to focus on advancing the rest of its best-in-class clinical portfolio.
Filing - Mar 30, 2026positive Pre-specified analysis (NPI-AA >=4, n=53): Cohen's d 0.34 on CMAI total and 0.51 on CMAI aggression sub-factor at Week 8, with favorable tolerability.
patients treated with NMRA-511 demonstrated a Cohen’s d effect size of 0.34 on the Cohen-Mansfield Agitation Inventory (CMAI) total score and 0.51 on the CMAI aggression sub-factor score at Week 8.
Filing
2 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.